');
} else {
var query = elem.find('.keywords').html();
$.ajax({
context: elem,
url: 'https://wn.com/api/upge/cheetah-search-adv/video',
cache: true,
data: {
'query': query
},
dataType: 'jsonp',
success: function(text) {
if (text.length > 0) {
video_id = text[0].id;
elem.find('.player').html('
');
}
}
});
}
}
var stopAllYouTubeVideos = function() {
var iframes = document.querySelectorAll('iframe');
Array.prototype.forEach.call(iframes, function(iframe) {
iframe.contentWindow.postMessage(JSON.stringify({ event: 'command', func: 'pauseVideo' }), '*');
});
}
jQuery(function() {
jQuery(".playVideo").live("click", function() {
if(!$(this).hasClass("played")){
stopAllYouTubeVideos();
var elem = $(this);
setTimeout(function(){
mouseOverMe(elem);
}, 1000);
}
});
jQuery(".description_box .expandContent").live("click", function() {
elem = $(this).parent().parent().parent().find('.descContent');
if(elem.height() > 51) {
elem.css('height', '44px');
$(this).html('Show More
');
}else{
elem.css('height', 'auto');
$(this).html('Hide
');
}
});
jQuery('.interview-play-off').click(function() {
$(".interview-play-off").hide();
$(".interview-play").show();
$(".videoplayer-control-pause").click();
});
jQuery(".video-desc .show_author_videos").live("click", function() {
query = $(this).attr('title');
container = $(this).parent().parent().parent().find('.video-author-thumbs');
$(this).parent().parent().parent().find('.video-author-thumbs').css('height', '220px');
jQuery.ajax({
url: '/api/upge/cheetah-photo-search/videoresults',
data: {'query': query},
success: function(text) {
if(!text) { text = i18n("No results"); }
container.html(jQuery(text));
}
});
});
});
// -->
Latest News for: top1
Edit
PR Newswire
30 Mar 2026
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor) ... IDEAYA has presented preclinical combination mechanism and synergy efficacy data of IDE161/PARG with TOP1-payload based ADCs at WCLC 2025.
Edit
Pharmiweb
28 Feb 2026
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161.
Edit
PR Newswire
25 Feb 2026
IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 dose escalation/expansion trial evaluating IDE034, an investigational PTK7/B7H3 bispecific TOP1 ADC.
The Daily Record - Dunn
30 Mar 2026